OBI 's Proprietary Enzyme EndoSymeOBI™ Featured on Cover of Prestigious International Journal, JACS Au.
2024.Apr.11
News
Poster Presentations at the AACR 2024 Annual Meeting for OBI-992 and GlycOBI™ ADC platform
2024.Jan.31
Announcement
Adagloxad Simolenin (OBI-822)/OBI-821, receives a positive 1st interim analysis recommendation, suggesting the continuation of the Phase III TNBC trial
2024.Jan.03
News
OBI Pharma Announces U.S. FDA Clearance of IND Application for a Phase 1/2 Study of OBI-992
Events
Investor
2024 Annual Shareholders’ Meeting
2024.Jun.17 at 09:00 AM
Masterlink Securities Education and Training Center
Event Time2024.Jun.17
Event LocationMasterlink Securities Education and Training Center
